Persistence of antigen is required to maintain transplantation tolerance induced by genetic modification of bone marrow stem cells

American Journal of Transplantation

Volumn 6, Issue 9, 2006, Pages 2202-2207

  Tian, C ^a   Bagley, J ^a   Iacomini, J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gene therapy; Stem cells; T cell; Transplantation tolerance

Indexed keywords

ALLOANTIGEN; ANTIGEN H2K B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Y 3; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; DONOR; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; TRANSPLANTATION TOLERANCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; GENE THERAPY; H-2 ANTIGENS; HEMATOPOIETIC STEM CELLS; MICE; RADIATION CHIMERA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 33746932112     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01455.x     Document Type: Article

References (35)

1. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400-401.
2. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953; 172: 603-606.
3. Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: Long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977; 146: 34-48.
4. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
5. Clift RA, Storb R. Histoincompatible bone marrow transplants in humans. Ann Rev Immunol 1987; 5: 43-64.
6. Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev 1997; 157: 73-78.
7. Williams MA, Adams AB,Walsh MB et al. Primary and secondary immunocompetence in mixed allogeneic chimeras. J Immunol 2003; 170: 2382-2389.
8. Daly A, McAfee S, Dey B et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9: 373-382.
9. Knechtle SJ. Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol 2000; 12: 552-556.
10. Toh HC, Spitzer TR, Preffer F et al. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant. Cytokines Cell Mol Ther 2002; 7: 43-47.
11. Dey BR, McAfee S, Colby C et al. Anti-tumour response despite loss of donor chimerism in patients treated with nonmyeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128: 351-359.
12. Bracy JL, Sachs DH, Iacomini J. Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science 1998; 281: 1845-1847.
13. Bracy JL, Iacomini J. Induction of B-cell tolerance by retroviral gene therapy. Blood 2000; 96: 3008-3015.
14. Bagley J, Tian C, Sachs DH, Iacomini J. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood 2002; 99: 4394-4399.
15. Tian C, Bagley J, Kaye J, Iacomini J. Induction of T cell tolerance to a protein expressed in the cytoplasm through retroviral-mediated gene transfer. J Gene Med 2003; 5: 359-365.
16. Tian C, Bagley J, Cretin N, Seth N, Wucherpfennig KW, Iacomini J. Prevention of type 1 diabetes by gene therapy. J Clin Invest 2004; 114: 969-978.
17. Xu B, Haviernik P, Wolfraim LA, Bunting KD, Scott DW. Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther 2006; 13: 42-48.
18. Ally BA, Hawley TS, McKall-Faienza KJ et al. Prevention of autoimmune disease by retroviral-mediated gene therapy. J Immunol 1995; 155: 5404-5408.
19. Bagley J, Iacomini J. Gene therapy progress and prospects: Gene therapy in organ transplantation. Gene Ther 2003; 10: 605-611.
20. Kang ES, Iacomini J. Induction of central deletional T cell tolerance by gene therapy. J Immunol 2002; 169: 1930-1935.
21. Forman D, Kang ES, Tian C, Paez-Cortez J, Iacomini J. Induction of alloreactive CD4 T cell tolerance in molecular chimeras: A possible role for regulatory T cells. J Immunol 2006; 176: 3410-3416.
22. Tian C, Bagley J, Iacomini J. Expression of antigen on mature lymphocytes is required to induce T cell tolerance by gene therapy. J Immunol 2002; 169: 3771-3776.
23. Tian C, Bagley J, Forman D, Iacomini J. Induction of central tolerance by mature T cells. J Immunol 2004; 173: 7217-7222.
24. Lubaroff DM, Silvers WK. Importance of chimerism in maintaining tolerance of skin allografts in mice. J Immunol 1973; 111: 65-71.
25. Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology 1993; 17: 1127-1152.
26. Starzl TE, Demetris AJ, Trucco M et al. Chimerism and donorspecific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55: 1272-1277.
27. Wood K, Sachs DH. Chimerism and transplantation tolerance: Cause and effect. Immunol Today 1996; 17: 584-587; discussion 588.
28. Bonilla WV, Geuking MB, Aichele P, Ludewig B, Hengartner H, Zinkernagel RM. Microchimerism maintains deletion of the donor cell-specific CD8+ T cell repertoire. J Clin Invest 2006; 116: 156-162.
29. Hammerling GJ, Rusch E, Tada N, Kimura S, Hammerling U. Localization of allodeterminants on H-2Kb antigens determined with monoclonal antibodies and H-2 mutant mice. Proc Natl Acad Sci U S A 1982; 79: 4737-4741.
30. Sawada T, Wu Y, Sachs DH, Iacomini J. CD4+ T cells are able to reject class I disparate allografts. Transplantation 1997; 64: 335-340.
31. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579-1582.
32. Hamano K, Rawsthorne MA, Bushell AR, Morris PJ, Wood KJ. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Transplantation 1996; 62: 856-860.
33. Sykes M, Sachs DH, Nienhuis AW, Pearson DA, Moulton AD, Bodine DM. Specific prolongation of skin graft survival following retroviral transduction of bone marrow with an allogeneic major histocompatibility complex gene. Transplantation 1993; 55: 197-202.
34. Fraser CC, Sykes M, Lee RS, Sachs DH, LeGuern C. Specific unresponsiveness to a retrovirally-transferred class I antigen is controlled through the helper pathway. J Immunol 1995; 154: 1587-1595.
35. Schumacher IK, Newberg MH, Jackson JD et al. Use of gene therapy to suppress the antigen-specific immune responses in mice to an HLA antigen. Transplantation 1996; 62: 831-836.